Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 3831 in Schizophrenia with Alcohol Use Disorder
NCT02161718Phase 2Completed
- Sponsor
- Alkermes
- Start
- May 2014
- Primary completion
- Jan 2017
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 3
01
Overview
A Phase 2 trial of olanzapine + samidorphan in schizophrenia, alcohol use disorder (AUD), sponsored by Alkermes. Started May 2014; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniaalcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT02161718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161718.